ION expands ETF trading capabilities with Tradeweb integration
BridgeBio Pharma Inc’s stock reached a 52-week high, hitting $72.36, marking a significant milestone for the company. According to InvestingPro data, the stock is currently trading above its Fair Value, with analysts setting price targets ranging from $65 to an ambitious $110. This surge reflects a remarkable 171.6% increase over the past year, showcasing strong investor confidence and positive market sentiment towards the company’s prospects. InvestingPro data reveals even more impressive metrics with a 161.59% year-to-date return and a substantial 102.43% gain over the past six months. The biotech firm’s recent advancements and strategic initiatives have likely contributed to this upward trajectory, positioning it favorably in the competitive landscape. With a market capitalization of $13.92 billion and revenue growth of 62.46%, BridgeBio demonstrates strong financial health with a current ratio of 3.88, indicating its liquid assets comfortably exceed short-term obligations. As BridgeBio continues to innovate and expand its pipeline, market observers will be keenly watching to see if this momentum can be sustained. Discover more insights with InvestingPro, where you’ll find 12 additional ProTips and a comprehensive Pro Research Report on BridgeBio.
In other recent news, BridgeBio Pharma reported its third-quarter 2025 earnings with a revenue of $120.7 million, surpassing expectations of $107.62 million. Despite a larger-than-expected loss with an EPS of -$0.95 compared to the forecast of -$0.88, the company’s revenue performance was strong. The impressive revenue results were driven by U.S. sales of Attruby, which reached $108.1 million, exceeding Goldman Sachs’ estimates by 11% and consensus estimates by 6%.
Analysts have responded positively to these developments. TD Cowen raised its price target for BridgeBio Pharma to $95, highlighting the 51% quarter-over-quarter sales growth of Attruby. Goldman Sachs also increased its price target to $100, citing the robust third-quarter earnings results. Similarly, Leerink Partners adjusted its price target to $75, acknowledging the strong sales figures and the company’s increase in unique prescriptions. These recent developments reflect a positive outlook from analysts regarding BridgeBio Pharma’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.